Guggenheim Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $9
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
Guggenheim analyst Vamil Divan initiates coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and announces Price Target of $9.
Guggenheim analyst Vamil Divan initiates coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and announces Price Target of $9.